Ocugen, Inc. OCGN
- OCU500 — COVID-19 Phase 1
- OCU520 — Influenza Preclinical
- OCU520 — COVID-19 Preclinical
Home › Targets › SARS-CoV-2 Spike protein
SARS-CoV-2 Spike protein (1 companies · 3 programs)
Companies with an active program directed at SARS-CoV-2 Spike protein.